Journal article
Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine
Abstract
BACKGROUND AND OBJECTIVES: Human papillomavirus (HPV) antibody responses to the 9-valent human papillomavirus (9vHPV) vaccine among girls and boys (aged 9-14 years) receiving 2-dose regimens (months 0, 6 or 0, 12) were noninferior to a 3-dose regimen (months 0, 2, 6) in young women (aged 16-26 years) 4 weeks after last vaccination in an international, randomized, open-label trial (NCT01984697). We assessed response durability through month 36.
Authors
Bornstein J; Roux S; Petersen LK; Huang L-M; Dobson SR; Pitisuttithum P; Diez-Domingo J; Schilling A; Ariffin H; Tytus R
Journal
, Vol. 147, No. 1,
Publisher
American Academy of Pediatrics (AAP)
Publication Date
January 1, 2021
DOI
10.1542/peds.2019-4035
ISSN
0031-4005